Zobrazeno 1 - 10
of 49
pro vyhledávání: '"V A Misyurin"'
Autor:
A E Misyurina, S K Kravchenko, A M Kovrigina, A U Magomedova, L V Plastinina, T N Obukhova, A V Misyurin, V A Misyurin, L A Grebenuk, F E Babaeva, E A Baryakh, A I Vorobiev
Publikováno v:
Терапевтический архив, Vol 91, Iss 7, Pp 52-62 (2019)
Aim of the issue was to compare clinical characteristics and treatment results of patients with follicular lymphoma (FL) with translocations involving loci of c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes and patients with high - grade B-cell lymphom
Externí odkaz:
https://doaj.org/article/57c54f39fbf94c129a713cef4676acaa
Autor:
A E Misyurina, S K Kravchenko, Ya K Mangasarova, A U Magomedova, A M Kovrigina, L T Shimanovskaya, E A Fastova, V A Misyurin, S V Model, D I Chebotarev, I E Kostina, V G Savchenko
Publikováno v:
Терапевтический архив, Vol 91, Iss 4, Pp 107-113 (2019)
Mediastinal gray-zone lymphoma (MGZL, lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma) was declared as a separate entity in WHO classification of Tumors of Haematopoetic and Lymphoid Tissues in
Externí odkaz:
https://doaj.org/article/7cbcda28488c4a5181098ce8cb8dfb7b
Autor:
E A Baryakh, A E Misyurina, A M Kovrigina, T N Obukhova, E G Gemdzhyan, V I Vorobyev, Ya K Mangasarova, Yu Yu Polyakov, A U Magomedova, G A Klyasova, V A Misyurin, G A Yatsyk, A A Shevelev, I E Kostina, A I Vorobyev, S K Kravchenko
Publikováno v:
Терапевтический архив, Vol 87, Iss 8, Pp 77-85 (2015)
Aim. To characterize a group of patients with B-cell lymphoma (BCLU) unclassified that is intermediate between diffuse large B-cell lymphoma and Burkitt’s lymphoma, to identify poor prognostic factors, and to evaluate therapeutic efficiency in pati
Externí odkaz:
https://doaj.org/article/2362b11853f643aea20cd73cb2af1c4f
Publikováno v:
Терапевтический архив, Vol 87, Iss 4, Pp 91-97 (2015)
B-cell lymphoma that is unclassifiable and intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt’s lymphoma (BL) — (UBL) is an aggressive lymphoma that has simultaneously morphological, immunophenotypical, and cytogenetic signs o
Externí odkaz:
https://doaj.org/article/95572ecab73a475e8d62563f06570295
Autor:
S. V. Saakyan, A. Yu. Tsygankov, A. G. Amiryan, M. R. Khlgatyan, D. A. Khochenkov, V. A. Misyurin
Publikováno v:
Успехи молекулярной онкологии, Vol 8, Iss 4, Pp 61-66 (2021)
The study objective is to analyze the prognostic significance of PRAME protein expression in patients with uveal melanoma using immunohistochemical assay.Materials and methods. A total of 30 patients with uveal melanoma were examined and treated. The
Externí odkaz:
https://doaj.org/article/72e34ad2f276463aae3dc1631ed94e54
Autor:
A. B. Danilova, T. L. Nekhaeva, V. A. Misyurin, N. A. Avdonkina, N. V. Emelyanova, I. A. Baldueva
Publikováno v:
Сибирский онкологический журнал, Vol 19, Iss 3, Pp 64-77 (2020)
Understanding of the sequence of events that ensure invasiveness of malignant cells is important for prognostic purposes. The study of the cellular and molecular pathways in the metastatic process lays the foundation for further progress in the treat
Externí odkaz:
https://doaj.org/article/7b5090111d65457d8d5dda6595576ce8
Autor:
A. A. Vartanian, O. S. Burova, Kh. S. Vishnyakova, I. V. Samoylenko, V. A. Misyurin, E. E. Egorov, O. O. Ryabaya, M. A. Baryshnikova
Publikováno v:
Успехи молекулярной онкологии, Vol 6, Iss 4, Pp 47-57 (2019)
Background. Activating mutations in the BRAF gene leads to a constitutive activation of the MAPK signaling. The highly selective BRAFV600E inhibitor, vemurafenib, improves the overall survival of BRAF-mutant melanoma patients. However, despite the ex
Externí odkaz:
https://doaj.org/article/2c60eba51be74945a5a4cbe6c09cdbeb
Autor:
L. A. Kesaeva, A. Yu. Bulanov, Yu. P. Finashutina, V. V. Tikhonova, O. N. Solopova, E. N. Misyurina, N. N. Kasatkina, N. A. Lyzhko, V. A. Misyurin, A. A. Turba, A. A. Solodovnik, I. N. Soldatova, A. V. Misyurin
Publikováno v:
Успехи молекулярной онкологии, Vol 6, Iss 2, Pp 48-54 (2019)
Molecular genetic detection of CALR gene somatic mutations is required for myeloproliferative neoplasms diagnosis and treatment according to the novel WHO clinical recommendations. CALR mutations are found in approximately 25–35 % cases of essentia
Externí odkaz:
https://doaj.org/article/ddc2d5ea07b847d58778f992b42fb958
Autor:
V. A. Misyurin, D. V. Kalenichenko, A. A. Rudakova, Yu. P. Finashutina, N. A. Lyzhko, V. V. Tikhonova, L. A. Kesaeva, O. N. Solopova, A. Е. Misyurina, A. N. Velikanov, M. А. Baryshnikovа, A. V. Misyurin
Publikováno v:
Успехи молекулярной онкологии, Vol 5, Iss 4, Pp 131-134 (2019)
Background. PRAME gene spontaneous expression is frequently observed in a cancer cell. The protein encoded by this gene increases the viability of tumour cell. NF-κB signalling pathway takes part in PRAME upregulation. It proposes, that stress condi
Externí odkaz:
https://doaj.org/article/87d06f320d814696885bc19a80580018
Autor:
S. G. Zakharov, A. K. Golenkov, V. A. Misyurin, E. V. Kataeva, M. A. Baryshnikova, Yu. Yu. Chuksina, T. A. Mitina, E. V. Trifonova, L. L. Vysotskaya, Yu. B. Chernykh, E. F. Klinushkina, K. A. Belousov, Yu. P. Finashutina, A. V. Misyurin
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 46, Iss 8, Pp 734-741 (2018)
Background: We have previously shown that the FAS, TNFR2, TRAIL, DR3, DR4/5 gene expression in patients with newly diagnosed chronic lymphoblastic leukemia (CLL) correlates with clinical manifestations of the disease: they are minimal in patients wit
Externí odkaz:
https://doaj.org/article/5700002fb2d745459e510326b80d8937